The abstract is read at the publisher; the summary is JClub's.
In 152 adults with hematologic cancer-related fatigue, methylphenidate improved FACIT-F fatigue scores by 8.9 points versus 3.9 with placebo, with a 5.0-point between-group advantage.
- Why it matters: Fatigue is the most frequent and severe unmet issue in hematologic cancers, and evidence for methylphenidate in this specific population has been limited.
- What they did: In a double-blind, placebo-controlled, two-period crossover trial, patients received 6 weeks of methylphenidate or placebo with a treatment-free week, and FACIT-F change from baseline was the primary endpoint.
- The result: Methylphenidate reduced fatigue on FACIT-F and other measures, with mild toxicity but more adverse events during methylphenidate periods (57% vs 40%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.